news

CUPERTINO, Calif., Jan. 30, 2017 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program.  DUR-928, our Epigenetic Regulator Program’s lead product candidate, is an endogenous, small molecule, new chemical entity (NCE), which may have broad applicability in several metabolic diseases such as nonalcoholic steatohepatitis (NASH) and other liver conditions, […]

CUPERTINO, Calif., Oct. 31, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2016.  Total revenues were $3.7 million and net loss was $8.8 million for the three months ended September 30, 2016 as compared to total revenues of $4.7 million and net loss of $6.5 million for

Initial data from Phase 1b study in NASH CUPERTINO, Calif., Oct. 31, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program including a description of data from the first cohort of a Phase 1b study with DUR-928 in patients with nonalcoholic steatohepatitis (NASH). “We are pleased to report

CUPERTINO, Calif., Oct. 21, 2016 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Monday, October 31, 2016 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio

CUPERTINO, Calif., Sept. 26, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Pain Therapeutics’ New Drug Application (NDA) for REMOXY® ER (oxycodone) extended-release capsules CII.  Based on its review, the FDA has determined that

CUPERTINO, Calif., Sept. 6, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Rodman & Renshaw Global Investment Conference on Monday, September 12 at 9:35 a.m. Eastern Time.  The conference is being held at the Lotte New York Palace Hotel in New York City. 

CUPERTINO, Calif., Aug. 1, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2016. Total revenues were $3.2 million and net loss was $9.0 million for the three months ended June 30, 2016 as compared to total revenues of $4.4 million and net loss of $5.5 million for the

CUPERTINO, Calif., July 25, 2016 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Monday, August 1, 2016 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast

Pain Therapeutics Announced today that an FDA Advisory Committee Meeting for REMOXY® is Not Needed and No Change to September 25, 2016 PDUFA Date CUPERTINO, Calif., July 1, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that the U.S. Food and Drug Administration (FDA) has

CUPERTINO, Calif., June 28, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Cantor Fitzgerald Healthcare Conference on Tuesday, July 12 at 8:00 a.m. Eastern Time.  The conference is being held at Le Parker Meridien Hotel in New York City.  Investors and analysts that